Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Emerging Themes for the Role of Antibodies in Tuberculosis.

Tran AC, Kim MY, Reljic R.

Immune Netw. 2019 Jul 29;19(4):e24. doi: 10.4110/in.2019.19.e24. eCollection 2019 Aug. Review.

2.

Inactivated Lactobacillus plantarum Carrying a Surface-Displayed Ag85B-ESAT-6 Fusion Antigen as a Booster Vaccine Against Mycobacterium tuberculosis Infection.

Kuczkowska K, Copland A, Øverland L, Mathiesen G, Tran AC, Paul MJ, Eijsink VGH, Reljic R.

Front Immunol. 2019 Jul 9;10:1588. doi: 10.3389/fimmu.2019.01588. eCollection 2019.

3.

Immunization With Mycobacterium tuberculosis Antigens Encapsulated in Phosphatidylserine Liposomes Improves Protection Afforded by BCG.

Diogo GR, Hart P, Copland A, Kim MY, Tran AC, Poerio N, Singh M, Paul MJ, Fraziano M, Reljic R.

Front Immunol. 2019 Jun 12;10:1349. doi: 10.3389/fimmu.2019.01349. eCollection 2019.

4.

Bacillus Calmette-Guérin Induces PD-L1 Expression on Antigen-Presenting Cells via Autocrine and Paracrine Interleukin-STAT3 Circuits.

Copland A, Sparrow A, Hart P, Diogo GR, Paul M, Azuma M, Reljic R.

Sci Rep. 2019 Mar 6;9(1):3655. doi: 10.1038/s41598-019-40145-0.

5.

High-resolution quantitative proteomics applied to the study of the specific protein signature in the sputum and saliva of active tuberculosis patients and their infected and uninfected contacts.

Mateos J, Estévez O, González-Fernández Á, Anibarro L, Pallarés Á, Reljic R, Gallardo JM, Medina I, Carrera M.

J Proteomics. 2019 Mar 20;195:41-52. doi: 10.1016/j.jprot.2019.01.010. Epub 2019 Jan 18.

PMID:
30660769
6.

VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy.

Fletcher HA, Chatterjee M, Cooper A, Hussell T, Kaye PM, Prior J, Reljic R, Vermaak S, Vordermeier M, Williams A, McShane H.

F1000Res. 2018 Apr 23;7:485. doi: 10.12688/f1000research.14386.1. eCollection 2018.

7.

A polymeric immunoglobulin-antigen fusion protein strategy for enhancing vaccine immunogenicity.

Webster GR, van Dolleweerd C, Guerra T, Stelter S, Hofmann S, Kim MY, Teh AY, Diogo GR, Copland A, Paul MJ, Hart P, Reljic R, Ma JK.

Plant Biotechnol J. 2018 Dec;16(12):1983-1996. doi: 10.1111/pbi.12932. Epub 2018 Jul 21.

8.

Mucosal Delivery of Fusion Proteins with Bacillus subtilis Spores Enhances Protection against Tuberculosis by Bacillus Calmette-Guérin.

Copland A, Diogo GR, Hart P, Harris S, Tran AC, Paul MJ, Singh M, Cutting SM, Reljic R.

Front Immunol. 2018 Mar 12;9:346. doi: 10.3389/fimmu.2018.00346. eCollection 2018.

9.

Nanoparticle-Fusion Protein Complexes Protect against Mycobacterium tuberculosis Infection.

Hart P, Copland A, Diogo GR, Harris S, Spallek R, Oehlmann W, Singh M, Basile J, Rottenberg M, Paul MJ, Reljic R.

Mol Ther. 2018 Mar 7;26(3):822-833. doi: 10.1016/j.ymthe.2017.12.016. Epub 2017 Dec 22.

10.

Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties.

Kim MY, Copland A, Nayak K, Chandele A, Ahmed MS, Zhang Q, Diogo GR, Paul MJ, Hofmann S, Yang MS, Jang YS, Ma JK, Reljic R.

Plant Biotechnol J. 2018 Jul;16(7):1283-1294. doi: 10.1111/pbi.12869. Epub 2018 Feb 1.

11.

Murine IL-4Δ2 splice variant down-regulates IL-4 activities independently of IL-4Rα binding and STAT-6 phosphorylation.

Diogo GR, Sparrow A, Paul MJ, Copland A, Hart PJ, Stelter S, van Dolleweerd C, Drake PMW, Macallan DC, Reljic R.

Cytokine. 2017 Nov;99:154-162. doi: 10.1016/j.cyto.2017.09.007. Epub 2017 Sep 13.

PMID:
28917204
12.

Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate.

Kim MY, Van Dolleweerd C, Copland A, Paul MJ, Hofmann S, Webster GR, Julik E, Ceballos-Olvera I, Reyes-Del Valle J, Yang MS, Jang YS, Reljic R, Ma JK.

Plant Biotechnol J. 2017 Dec;15(12):1590-1601. doi: 10.1111/pbi.12741. Epub 2017 Jul 15.

13.

Oral immunisation of mice with transgenic rice calli expressing cholera toxin B subunit fused to consensus dengue cEDIII antigen induces antibodies to all four dengue serotypes.

Kim MY, Kim BY, Oh SM, Reljic R, Jang YS, Yang MS.

Plant Mol Biol. 2016 Oct;92(3):347-56. doi: 10.1007/s11103-016-0517-0. Epub 2016 Aug 26.

PMID:
27566485
14.

Reconciling Estimates of Cell Proliferation from Stable Isotope Labeling Experiments.

Ahmed R, Westera L, Drylewicz J, Elemans M, Zhang Y, Kelly E, Reljic R, Tesselaar K, de Boer RJ, Macallan DC, Borghans JA, Asquith B.

PLoS Comput Biol. 2015 Oct 5;11(10):e1004355. doi: 10.1371/journal.pcbi.1004355. eCollection 2015 Oct.

15.

Novel vaccination approach for dengue infection based on recombinant immune complex universal platform.

Kim MY, Reljic R, Kilbourne J, Ceballos-Olvera I, Yang MS, Reyes-del Valle J, Mason HS.

Vaccine. 2015 Apr 8;33(15):1830-8. doi: 10.1016/j.vaccine.2015.02.036. Epub 2015 Feb 26.

PMID:
25728317
16.

Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV.

Paul M, Reljic R, Klein K, Drake PM, van Dolleweerd C, Pabst M, Windwarder M, Arcalis E, Stoger E, Altmann F, Cosgrove C, Bartolf A, Baden S, Ma JK.

MAbs. 2014;6(6):1585-97. doi: 10.4161/mabs.36336.

17.

Development of a new tuberculosis vaccine: is there value in the mucosal approach?

Diogo GR, Reljic R.

Immunotherapy. 2014;6(9):1001-13. doi: 10.2217/imt.14.62. Review.

PMID:
25341121
18.

Recombinant Bacillus subtilis spores expressing MPT64 evaluated as a vaccine against tuberculosis in the murine model.

Sibley L, Reljic R, Radford DS, Huang JM, Hong HA, Cranenburgh RM, Cutting SM.

FEMS Microbiol Lett. 2014 Sep;358(2):170-9. doi: 10.1111/1574-6968.12525. Epub 2014 Jul 22.

19.

Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG.

Pepponi I, Diogo GR, Stylianou E, van Dolleweerd CJ, Drake PM, Paul MJ, Sibley L, Ma JK, Reljic R.

Plant Biotechnol J. 2014 Sep;12(7):840-50. doi: 10.1111/pbi.12185. Epub 2014 Mar 13.

20.

Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice.

Stylianou E, Diogo GR, Pepponi I, van Dolleweerd C, Arias MA, Locht C, Rider CC, Sibley L, Cutting SM, Loxley A, Ma JK, Reljic R.

Eur J Immunol. 2014 Feb;44(2):440-9.

21.

Mucosal vaccination against tuberculosis using inert bioparticles.

Reljic R, Sibley L, Huang JM, Pepponi I, Hoppe A, Hong HA, Cutting SM.

Infect Immun. 2013 Nov;81(11):4071-80. doi: 10.1128/IAI.00786-13. Epub 2013 Aug 19.

22.

Immune-complex mimics as a molecular platform for adjuvant-free vaccine delivery.

Pepponi I, Stylianou E, van Dolleweerd C, Diogo GR, Paul MJ, Drake PM, Ma JK, Reljic R.

PLoS One. 2013 Apr 23;8(4):e60855. doi: 10.1371/journal.pone.0060855. Print 2013.

23.

Molecular Pharming: future targets and aspirations.

Paul M, van Dolleweerd C, Drake PM, Reljic R, Thangaraj H, Barbi T, Stylianou E, Pepponi I, Both L, Hehle V, Madeira L, Inchakalody V, Ho S, Guerra T, Ma JK.

Hum Vaccin. 2011 Mar;7(3):375-82. Epub 2011 Mar 1. Review.

24.

Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice.

Stylianou E, Pepponi I, van Dolleweerd CJ, Paul MJ, Ma JK, Reljic R.

Vaccine. 2011 Mar 9;29(12):2279-86. doi: 10.1016/j.vaccine.2011.01.030. Epub 2011 Jan 25.

PMID:
21272603
25.

A novel human IgA monoclonal antibody protects against tuberculosis.

Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Kooten C, van Egmond M, Challacombe S, Woof JM, Ivanyi J.

J Immunol. 2011 Mar 1;186(5):3113-9. doi: 10.4049/jimmunol.1003189. Epub 2011 Jan 21.

26.

Generation of self-renewing immature dendritic cells from mouse spleen that can take up mycobacteria and present antigens to T cells.

Pal R, Marwaha S, Pepponi I, Mann JF, Paul MJ, Reljic R.

APMIS. 2010 Oct;118(10):729-38. doi: 10.1111/j.1600-0463.2010.02650.x.

PMID:
20854466
27.

Cytokine interactions that determine the outcome of Mycobacterial infection of macrophages.

Reljic R, Stylianou E, Balu S, Ma JK.

Cytokine. 2010 Jul;51(1):42-6. doi: 10.1016/j.cyto.2010.04.005.

PMID:
20434357
28.

Social leverage of intellectual property: road to the development of better therapy for tuberculosis.

Thangaraj H, Reljic R.

Recent Pat Antiinfect Drug Discov. 2009 Jun;4(2):114-22. Review.

PMID:
19519546
29.

TNF-alpha in tuberculosis: a cytokine with a split personality.

Mootoo A, Stylianou E, Arias MA, Reljic R.

Inflamm Allergy Drug Targets. 2009 Mar;8(1):53-62. Review.

PMID:
19275693
30.

Cytokine therapy of tuberculosis at the crossroads.

Reljic R, Paul MJ, Arias MA.

Expert Rev Respir Med. 2009 Feb;3(1):53-66. doi: 10.1586/17476348.3.1.53.

PMID:
20477282
31.

Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy.

Buccheri S, Reljic R, Caccamo N, Meraviglia S, Ivanyi J, Salerno A, Dieli F.

Tuberculosis (Edinb). 2009 Jan;89(1):91-4. doi: 10.1016/j.tube.2008.09.001. Epub 2008 Nov 5.

PMID:
18986840
32.

IFN-gamma therapy of tuberculosis and related infections.

Reljic R.

J Interferon Cytokine Res. 2007 May;27(5):353-64. Review.

PMID:
17523867
33.

IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice.

Buccheri S, Reljic R, Caccamo N, Ivanyi J, Singh M, Salerno A, Dieli F.

Eur J Immunol. 2007 Mar;37(3):729-37.

34.

A case for passive immunoprophylaxis against tuberculosis.

Reljic R, Ivanyi J.

Lancet Infect Dis. 2006 Dec;6(12):813-8.

PMID:
17123901
35.

In search of the elusive mouse macrophage Fc-alpha receptor.

Reljic R.

Immunol Lett. 2006 Sep 15;107(1):80-1. Epub 2006 Jun 27.

PMID:
16837064
36.

Mucosal immunotherapy of tuberculosis: is there a value in passive IgA?

Reljic R, Williams A, Ivanyi J.

Tuberculosis (Edinb). 2006 May-Jul;86(3-4):179-90. Epub 2006 Feb 28. Review.

PMID:
16510311
37.

Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.

Reljic R, Clark SO, Williams A, Falero-Diaz G, Singh M, Challacombe S, Marsh PD, Ivanyi J.

Clin Exp Immunol. 2006 Mar;143(3):467-73.

38.

The structure of human CD23 and its interactions with IgE and CD21.

Hibbert RG, Teriete P, Grundy GJ, Beavil RL, Reljic R, Holers VM, Hannan JP, Sutton BJ, Gould HJ, McDonnell JM.

J Exp Med. 2005 Sep 19;202(6):751-60.

39.

Time course of mycobacterial infection of dendritic cells in the lungs of intranasally infected mice.

Reljic R, Di Sano C, Crawford C, Dieli F, Challacombe S, Ivanyi J.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):81-8. Epub 2004 Dec 23.

PMID:
15687031
40.

Mouse monoclonal IgA binds to the galectin-3/Mac-2 lectin from mouse macrophage cell lines.

Reljic R, Crawford C, Challacombe S, Ivanyi J.

Immunol Lett. 2004 Apr 30;93(1):51-6.

PMID:
15134899
41.

Mouse IgA inhibits cell growth by stimulating tumor necrosis factor-alpha production and apoptosis of macrophage cell lines.

Reljic R, Crawford C, Challacombe S, Ivanyi J.

Int Immunol. 2004 Apr;16(4):607-14.

PMID:
15039391
42.

Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs.

Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M, Challacombe S, Marsh PD, Ivanyi J.

Immunology. 2004 Mar;111(3):328-33.

43.
44.

Function of CD23 in the response of human B cells to antigen.

Reljić R, Cosentino G, Gould HJ.

Eur J Immunol. 1997 Feb;27(2):572-5.

PMID:
9045933
45.

New chromogen for assay of glucose in serum.

Reljic R, Ries M, Anić N, Ries B.

Clin Chem. 1992 Apr;38(4):522-5.

46.

Expression, glycosylation and secretion of yeast acid phosphatase in hamster BHK cells.

Reljic R, Barbaric S, Ries B, Buxton R, Hughes RC.

Glycoconj J. 1992 Feb;9(1):39-44.

PMID:
1392564

Supplemental Content

Loading ...
Support Center